Clinical trial · Observational
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
Real-world Experience of Immunotherapy Plus Chemotherapy as First-line Treatment With or Without Radiotherapy for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China
NCT06190652CI-TRIAL-00073613REICRAEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy combined with immunotherapy | Drug | — | UNRESOLVED |
| radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Arm A
- description
- Chemotherapy combined with immunotherapy group
- interventionNames
- Drug: Chemotherapy combined with immunotherapy
- label
- Arm B
- description
- Chemotherapy combined with immunotherapy + radiotherapy group
- interventionNames
- Drug: Chemotherapy combined with immunotherapy
- Radiation: radiotherapy
Primary outcomes (1)
- measure
- PFS
- timeFrame
- up to 2 years
- description
- progression-free survival
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically diagnosed as esophageal squamous cell carcinoma; 2. The clinical stage is IVb stage, that is, non-regional lymph node metastasis and distant organ metastasis (AJCC8th) of esophageal carcinoma. 3. Patients had received no previous systemic therapy 4. Patients who had received at least one cycle of first-line chemotherapy combined with immunotherapy, received or did not receive radiotherapy; 5. Complete medical records; 6. ECOG0-2; Exclusion Criteria: 1. Surgery for esophageal cancer; 2. Esophageal fistulae due to infiltration of the primary tumour. 3. Risk of gastrointestinal bleeding, oesophageal fistula or oesophageal perforation 4. Those who have a history of autoimmune disease or have been treated with immunosuppressants within the last 3 months. 5. Those who have received organ transplant surgery. 6. Patients with a previous history of malignant tumor (skin basal cell carcinoma and cervical carcinoma in situ) survived tumor-free for 3 years after treatment. Except for the above). 7. There are other serious diseases, such as myocardial infarction, cerebral infarction or severe cardiopulmonary insufficiency within 6 months
References
Publications (0)
Data not yet available
No reference posted for this study.